Integration of cyclodextrins and associated toxicities : A roadmap for high quality biomedical applications
Copyright © 2022 Elsevier Ltd. All rights reserved..
Cyclodextrins are extensively employed in drug delivery systems like inclusion complexes, metal-organic frameworks, functionalized or PEGylated conjugates, and other nanocarrier systems such as nanosponges or hydrogel nanoparticles for targeted effect or prolonged release action. Applications of CDs range from drug-loaded nanocarrier systems useful for disease conditions (such as cancer, diabetes, and bacterial infections, etc.) to supramolecular chemistry, diagnostics, imaging, biosensors, and medical devices. However, there is a limited data and information on the adverse effects caused by cyclodextrins and their toxicities in the medical field. Various in-vitro and ex-vivo toxic effects such as cytotoxicity, ototoxicity, etc. as well as the adverse and toxic effects depend on the role of administration of cyclodextrins. This review article focuses on the advancement of characteristics, properties and chemistry of cyclodextrins and addresses the new challenges faced in cyclodextrin-based delivery systems and the various toxicities induced by them.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:295 |
|---|---|
| Enthalten in: |
Carbohydrate polymers - 295(2022) vom: 01. Nov., Seite 119880 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Trotta, Francesco [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adverse effect |
|---|
| Anmerkungen: |
Date Completed 23.08.2022 Date Revised 23.08.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.carbpol.2022.119880 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34507517X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34507517X | ||
| 003 | DE-627 | ||
| 005 | 20231226024241.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.carbpol.2022.119880 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1150.xml |
| 035 | |a (DE-627)NLM34507517X | ||
| 035 | |a (NLM)35988985 | ||
| 035 | |a (PII)S0144-8617(22)00785-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Trotta, Francesco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Integration of cyclodextrins and associated toxicities |b A roadmap for high quality biomedical applications |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.08.2022 | ||
| 500 | |a Date Revised 23.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Cyclodextrins are extensively employed in drug delivery systems like inclusion complexes, metal-organic frameworks, functionalized or PEGylated conjugates, and other nanocarrier systems such as nanosponges or hydrogel nanoparticles for targeted effect or prolonged release action. Applications of CDs range from drug-loaded nanocarrier systems useful for disease conditions (such as cancer, diabetes, and bacterial infections, etc.) to supramolecular chemistry, diagnostics, imaging, biosensors, and medical devices. However, there is a limited data and information on the adverse effects caused by cyclodextrins and their toxicities in the medical field. Various in-vitro and ex-vivo toxic effects such as cytotoxicity, ototoxicity, etc. as well as the adverse and toxic effects depend on the role of administration of cyclodextrins. This review article focuses on the advancement of characteristics, properties and chemistry of cyclodextrins and addresses the new challenges faced in cyclodextrin-based delivery systems and the various toxicities induced by them | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Adverse effect | |
| 650 | 4 | |a Complexation | |
| 650 | 4 | |a Cytotoxicity | |
| 650 | 4 | |a Functionalization | |
| 650 | 4 | |a Inclusion | |
| 650 | 7 | |a Cyclodextrins |2 NLM | |
| 650 | 7 | |a Hydrogels |2 NLM | |
| 700 | 1 | |a Loftsson, Thorsteinn |e verfasserin |4 aut | |
| 700 | 1 | |a Gaud, R S |e verfasserin |4 aut | |
| 700 | 1 | |a Trivedi, Riddhi |e verfasserin |4 aut | |
| 700 | 1 | |a Shende, Pravin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Carbohydrate polymers |d 1994 |g 295(2022) vom: 01. Nov., Seite 119880 |w (DE-627)NLM082819491 |x 1879-1344 |7 nnns |
| 773 | 1 | 8 | |g volume:295 |g year:2022 |g day:01 |g month:11 |g pages:119880 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.carbpol.2022.119880 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 295 |j 2022 |b 01 |c 11 |h 119880 | ||